Genomic and immune indicators can help identify prostate cancer patients at high risk of lethal outcomes
Prostate cancer is one of the most common cancers among men in the United States. One in nine men will be diagnosed during his lifetime. When diagnosed, a patient s disease is graded from 1 to 5 based on how aggressive it is, with 5 being the most aggressive. Those with grades 4/5 disease are at the highest risk of poor outcomes or death from the disease; however, there are no immunologic or genomic indicators that can help physicians determine the best course of treatment for this group of patients.